Chemosensitizing Effects of Resveratrol Derivatives on p53-dependent Apoptosis Triggered by Cisplatin in Human Lung Cancer Cells

View at publisher Summarise with VIRAT
Authors: THANAWUT PRAMUALSIN, Zin Zin, Satapat Racha, Nicharat Sriratanasak, Masashi Yokoya, YUKIHA IIDA, Pithi Chanvorachote
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND/AIM: Although cisplatin is a standard treatment for lung cancer, its effectiveness is often limited by tumor chemoresistance and severe side effects, driving the search for approaches that can restore drug sensitivity. Resveratrol (Res) exhibits anticancer properties, but its clinical application is hindered by poor stability and low bioavailability. This study investigated the chemosensitization effect of YI-7, a Res derivative with modified pharmacophore benzyloxy substitutions that sensitized to p53-dependent apoptosis triggered by cisplatin in human lung cancer cells. MATERIALS AND METHODS: of YI-7 in A549 human lung cancer cells was determined using the MTT viability assay. Cell proliferation was further examined using a colony formation assay. Chemosensitizing effects were assessed by pretreating cells with cisplatin (25 μM), followed by YI-7, and analyzing cell viability (MTT), nuclear staining (Hoechst 33342/PI), and apoptosis-associated proteins using western blot. RESULTS: 137.90±11.48 μM) and dose-dependently inhibited colony formation, with marked suppression at 50 μM. Moreover, YI-7 pretreatment synergistically enhanced cisplatin cytotoxicity in A549 cells, with Combination Index (CI) values

Fields of Study & Subjects

Sirtuins and Resveratrol in Medicine Cancer-related Molecular Pathways Histone Deacetylase Inhibitors Research

Publication details

Journal / source
Anticancer Research
Volume
46
Issue
4
Pages
1893–1901
Publication date
27 March 2026
Language
EN